Featured Research

from universities, journals, and other organizations

Immune protein fends off exotic virus

Date:
February 4, 2010
Source:
Rockefeller University Press
Summary:
A study shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus. This pathogen, which causes high fevers and severe joint pain, triggered a recent epidemic in Southeast Asia, infecting more than 30 percent of the population in some areas.

A study published online on February 1 in the Journal of Experimental Medicine shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.

This pathogen, which causes high fevers and severe joint pain, triggered a recent epidemic in Southeast Asia, infecting more than 30% of the population in some areas.

A team led by Marc Lecuit and Matthew Albert at the Pasteur Institute in Paris found that individuals infected with Chikungunya virus had increased levels of type I IFNs in their blood. But the source of the virus-fighting IFN proteins came as a surprise. Viruses related to Chikungunya trigger type I IFN production mostly from immune cells. But during Chikungunya infection, immune cells neither produced nor responded to type I IFNs. Rather non-immune cells called fibroblasts -- the main target of virus infection -- provided the essential type I IFN.

This unique feature should be taken into consideration in future efforts to develop therapeutic strategies for controlling Chikungunya virus infection.

Reference: Schilte, C., et al. 2010. J. Exp. Med. doi:10.1084/jem.20090851.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University Press. "Immune protein fends off exotic virus." ScienceDaily. ScienceDaily, 4 February 2010. <www.sciencedaily.com/releases/2010/02/100201091622.htm>.
Rockefeller University Press. (2010, February 4). Immune protein fends off exotic virus. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/02/100201091622.htm
Rockefeller University Press. "Immune protein fends off exotic virus." ScienceDaily. www.sciencedaily.com/releases/2010/02/100201091622.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins